Neurodegeneration News and Research

RSS

Neurodegeneration is the umbrella term for the progressive loss of structure or function of neurons, including death of neurons.

Alzheimer's may spread through connected neurons

Alzheimer's disease and other forms of dementia may spread within nerve networks in the brain by moving directly between connected neurons, instead of in other ways proposed by scientists, such as by propagating in all directions, according to researchers who report the finding in the March 22 edition of the journal Neuron.

22 Mar 2012

Researchers show how errant form of LYP can disrupt the immune system

Autoimmune diseases, such as Type I diabetes and rheumatoid arthritis, are caused by an immune system gone haywire, where the body's defense system assaults and destroys healthy tissues. A mutant form of a protein called LYP has been implicated in multiple autoimmune diseases, but the precise molecular pathway involved has been unknown.

19 Mar 2012

NEJM publishes results from Teva's laquinimod Phase III study on RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced the publication of results from the laquinimod Phase III ALLEGRO study in the March 15 issue of The New England Journal of Medicine.

16 Mar 2012

Study identifies 190 proteins crucial to the functions of key immune sensors

In a healthy immune system, invading pathogens trigger a cascade of alerts and responses to fight off the infection. Sensors called toll-like receptors, or TLRs, act as one of the first lines of defense. Two of these sensors, known as TLR7 and TLR9, specifically recognize and respond to microbial RNA and DNA, respectively. But what determines how these TLRs get where they need to be and sound the alarm for pathogen infection?

15 Mar 2012

New RAGE inhibitor shows promise against Alzheimer's

Researchers have taken another crack at a promising approach to stopping Alzheimer's disease that encountered a major hurdle last year. In research published this week in the Journal of Clinical Investigation, scientists have developed a compound that targets a molecular actor known as RAGE, which plays a central role in mucking up the brain tissue of people with the disease.

15 Mar 2012

Human diseases with Drosophila counterparts discussed at annual conference

More than two-thirds of human genes have counterparts in the well-studied fruit fly, Drosophila melanogaster, so although it may seem that humans don't have much in common with flies, the correspondence of our genetic instructions is astonishing. In fact, there are hundreds of inherited diseases in humans that have Drosophila counterparts.

12 Mar 2012

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the company's ANTISENILIN monoclonal antibody platform technology for the treatment and prevention of Alzheimer's disease.

7 Mar 2012

Alzheimer's disease drugs may act like a bad electrician

Alzheimer's disease drugs now being tested in clinical trials may have potentially adverse side effects, according to new Northwestern Medicine research. A study with mice suggests the drugs could act like a bad electrician, causing neurons to be miswired and interfering with their ability to send messages to the brain.

29 Feb 2012

Targeting O-GlcNAcase enzyme with inhibitors might treat Alzheimer's

Slowing or preventing the development of Alzheimer's disease, a fatal brain condition expected to hit one in 85 people globally by 2050, may be as simple as ensuring a brain protein's sugar levels are maintained.

29 Feb 2012

ALS Association, AAN to honor KCL neurologist with Essey Award

The American Academy of Neurology and the ALS Association are awarding the 2012 Sheila Essey Award: An Award for ALS Research to Christopher Shaw, MBChB, MD, FRACP, with the Institute of Psychiatry at King's College London. Shaw will receive the award during the Academy's 64th Annual Meeting, April 21-28, 2012, in New Orleans.

22 Feb 2012

Fast once or twice a week to improve brain health and prolong life

According to a team from the National Institute on Ageing in Baltimore, America, fasting for one or two days a week may protect against Alzheimer’s, Parkinson’s and other degenerative brain conditions.

20 Feb 2012

U.S. FDA accepts Pfizer's tafamidis NDA for treatment of TTR-FAP

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tafamidis meglumine, the company's investigational, novel, oral therapy for the treatment of Transthyretin Familial Amyloid Polyneuropathy.

16 Feb 2012

New group of compounds may protect brain cells from inflammation

Scientists at Emory University School of Medicine have identified a new group of compounds that may protect brain cells from inflammation linked to seizures and neurodegenerative diseases.

15 Feb 2012

Scientists create new mouse model for medulloblastoma

Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) developed a new mouse model for studying a devastating childhood brain cancer called medulloblastoma.

14 Feb 2012

Scientists identify single prion protein that causes neuronal death

Scientists from the Florida campus of The Scripps Research Institute have identified a single prion protein that causes neuronal death similar to that seen in "mad cow" disease, but is at least 10 times more lethal than larger prion species.

10 Feb 2012

Sanford-Burnham, Florida Hospital and Moffitt partner to develop PMP Florida

Moffitt Cancer Center, Sanford-Burnham Medical Research Institute and Florida Hospital have announced they will collaborate on the creation of a Personalized Medicine Partnership of Florida (PMP Florida). The partnership will conduct collaborative research to accelerate discovery and develop new treatments in the areas of cancer and metabolic diseases, including obesity, diabetes and cardiovascular disease.

9 Feb 2012

Body's zinc control mechanisms may be key to aggressive breast cancer treatments

The body's control mechanisms for delivering zinc to cells could be key to improving treatment for some types of aggressive breast cancer.

6 Feb 2012

Scientists identify molecular switch that controls ATF2's dual functions

The National Cancer Institute (NCI) estimates that as many as one in 51 men and women will be diagnosed with melanoma-the deadliest form of skin cancer-at some point during their lifetimes. A research team led by Ze'ev Ronai, Ph.D. at Sanford-Burnham Medical Research Institute (Sanford-Burnham) is working to unravel the molecular mechanisms underlying the development and progression of this disease in hopes of improving prevention and treatment strategies

3 Feb 2012

Researchers reveal how antipsychotics affect metabolism by SMAD3 activation

In a paper published January 31 in the journal Molecular Psychiatry, researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) reveal how antipsychotic drugs interfere with normal metabolism by activating a protein called SMAD3, an important part of the transforming growth factor beta (TGFbeta) pathway.

2 Feb 2012

Power3, Amarantus sign license agreement for NuroPro Blood Test for Parkinson's

Amarantus BioSciences, Inc., a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein being developed for the treatment of Parkinson's Disease, today announced an exclusive worldwide license agreement with Power3 Medical Products, Inc. for the NuroPro Blood Test as it relates to Parkinson's disease diagnosis.

24 Jan 2012